Skip to main content
GutCited

L-Glutamine für Crohn's Disease

C

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Fazit

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

Key Study Findings

Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None vs.: None Outcome: Gut microbiota composition Wirkung: None None

Population: Crohn's disease patients

Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT) vs.: Pre-treatment baseline Outcome: Clinical remission and multi-omics changes Wirkung: None None

Population: Patients with Crohn's disease

Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None vs.: None Outcome: Cholesterol levels Wirkung: None None

Population: Mouse model

Observational Study n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured) vs.: Healthy controls (n=126) Outcome: PAGln association with CD and colitis Wirkung: None None

Population: New-onset treatment-naive CD (n=136) + controls

In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic) vs.: Wild-type mice Outcome: Cytokine production in macrophage activation Wirkung: None None

Population: Beclin1 variant mice + AIEC infection

Review
[Regulation of inflammatory bowel disease by amino acids].
Dose: None vs.: None Outcome: None Wirkung: None None

Population: IBD patients

Key Statistics

3

Studien

200

Teilnehmer

Positive

C

Bewertung

Referenced Papers

Sheng wu gong … 2022 4 Zitierungen
The Cochrane database … 2018 425 Zitierungen
Gastroenterology clinics of … 2018 67 Zitierungen
Current opinion in … 2017 37 Zitierungen
The Cochrane database … 2016 37 Zitierungen
Inflammatory bowel diseases 2010 89 Zitierungen
Molecular nutrition & … 2008 26 Zitierungen
The Cochrane database … 2007 192 Zitierungen
Current opinion in … 2005 22 Zitierungen
Clinical nutrition (Edinburgh, … 2004 18 Zitierungen
Medycyna wieku rozwojowego 2004 1 Zitierungen
Alimentary pharmacology & … 2003 179 Zitierungen
Revista do Hospital … 2002 39 Zitierungen
Current opinion in … 2002 1 Zitierungen
Current opinion in … 2002
The Cochrane database … 2001 149 Zitierungen
Current opinion in … 2000 21 Zitierungen
Diseases of the … 1998 26 Zitierungen
Zeitschrift fur Gastroenterologie 1998 18 Zitierungen
Schweizerische medizinische Wochenschrift. … 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
5-15 g/day
ibsdsupport:
5 g three times daily (15 g/day total)
postexercisegut:
0.25-0.9 g/kg before intense exercise
gutbarriersupport:
0.5 g/kg/day (approximately 30-40 g/day for adults)

Obergrenze: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Positive --
Washed microbiota transplantation (WMT) -- Positive --
None -- Positive --
Phenylacetylglutamine (PAGln, measured) -- Negative 262
Beclin1 constitutive activation (genetic) -- Positive --
None -- Mixed --
None -- Negative --
None -- Mixed --

Beste Einnahmezeit: Between meals or before exercise; divide doses throughout the day

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Mild gastrointestinal discomfort at high doses
  • Headache
  • Dizziness at very high doses
  • Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)

Bekannte Wechselwirkungen

  • Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
  • Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
  • Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)

Tolerierbare Höchstaufnahmemenge: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.